FindTrial
Sign In

Recurrent chronic cough, wheeze triggered by RS virus infection and their control with leukotriene receptor antagonists (LTRAs: montelukast, pranlukast), carbocystein and ambroxol

Recurrent chronic cough, wheeze triggered by RS virus infection and their control with leukotriene receptor antagonists (LTRAs: montelukast, pranlukast), carbocystein and ambroxol - Recurrent chronic cough, wheeze triggered by RS virus infection and their control

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024787
Enrollment
50
Registered
2016-11-15
Start date
2016-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent chronic cough, wheeze triggered by RS virus infection during early childhood

Interventions

Control (LTRA only, for 6 months to one year) +treatment (LTRA + carbocystein and ambroxol, for 6 months to one year)

Sponsors

Department of Pediatrics, Hiroshima City Hospital
Lead Sponsor
Okayama University Hospital Nihon-Kokan Fukuyama Hospital Osaka Center of Respiratology and Allergy Dokkyomedical School Hospital Nagano Red Cross Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: RS virus-infected children who suffered from bronchiolitis and was considered for hospitalization (SpO2 < 92%)

Exclusion criteria

Exclusion criteria: excluding typical atopic patients (IgE <150 IU)

Design outcomes

Primary

MeasureTime frame
1) Main evaluation Decrease in freequency of wheezing and chronic cough (every 1-2 months).—

Secondary

MeasureTime frame
2) Second evaluation Modified ACT test (cough, sleepless, activity), frequency of respiratory accidents.—

Countries

Japan

Contacts

Public ContactYoshiharu Nagaoka

Hiroshima City Hospital Department of Pediatrics

y.nagaoka@city-hosp.naka.hiroshima.jp082-221-2291

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026